Rubius Therapeutics, Inc., a prominent biopharmaceutical venture, is devoted to pioneering cutting-edge red cell therapeutics as a means of treating cancer and autoimmune diseases. The firm was once known by the moniker VL26, Inc.; yet, in 2015, underwent a rebranding initiative and adopted its present-day name. Rubius Therapeutics was established in 2013 and is headquartered in Foxborough, Massachusetts.